|Bid||1.99 x 1000|
|Ask||1.99 x 2200|
|Day's Range||1.9000 - 2.0600|
|52 Week Range||1.2900 - 3.0900|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2019 - Mar 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
The direct benefit for Athersys Inc (NASDAQ:ATHX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
Management to host conference call at 4:30pm EST today CLEVELAND, Nov. 06, 2018 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CLEVELAND, Ohio, Oct. 09, 2018 -- Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday,.
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from ...
CEO invited to provide corporate overview and speak in two workshops focusing on innovative development initiatives in Japan and advanced manufacturing technologies. CLEVELAND, Ohio, Sept. 24, 2018-- Athersys, ...
A look at the shareholders of Athersys Inc (NASDAQ:ATHX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to seeRead More...
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To ...
HENDERSON, NV / ACCESSWIRE / July 12, 2018 / The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to a new report by Grand View Research, Inc. With that being said this market could bring incredible value to shareholders of regenerative medicine companies over the next several years. With BioRestorative Therapies, Inc. (BRTX) we noticed that the market cap of this company is so low it could very well have a lot of room to grow.
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).